CD72

Across TCGA pan-cancer cohorts, CD72 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CD72 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CD72 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CD72 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where CD72 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.794	0.290	.001	31	view →
LUAD	OS	Tertile	II,III,IV	0.328	0.765	.012	8	view →
CCRCC	DFS	Median	IV	0.200	0.887	.038	6	view →
LSCC	OS	Tertile	II,III,IV	0.476	0.895	.025	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CD72–PDAC (DFS)

Open the PDAC breakdown →